Xeris Pharmaceuticals Inc., of Chicago, gained FDA orphan status for its ready-to-use, liquid-stable glucagon for the treatment of hyperinsulinemic hypoglycemia (HH). HH is associated with several diseases, including post-bariatric hypoglycemia (PBH).